Argon laser trabeculoplasty has gained widespread acceptance as a valuable tool for the control of glaucoma. Its efficacy in the short term has been established,' 2 and recent reports are encouraging with regard to long term control."7 Its mode of action has not been clearly elucidated, though an increase in outflow facility has been demonstrated.' =" A variety of complications of laser trabeculoplasty have been reported,'2-'6 the most serious being an immediate rise in intraocular pressure. Eyes already severely compromised by chronically raised intraocular pressure are susceptible to further damage from acute pressure elevations which may lead to field loss or loss of central vision.' 12 14 15 17 It has been suggested that the extent of trabecular meshwork treated, as well as the number of burns, their energy, and placement, have a bearing on the degree of the pressure rise; though attention to these details may reduce the incidence of raised pressure, they do not eradicate it. "'" Several forms of pretreatment, including topical 4% pilocarpine, 2 the frequency and severity of the pressure rise, while pretreatment with topical corticosteroid,2" indomethacin,27-' and flurbiprofen'3' had no statistically significant effect.
We performed a prospective, randomised, doublemasked study to evaluate the effectiveness of oral acetazolamide in preventing this pressure rise. A significant rise of IOP after argon laser trabeculoplasty is usually apparent by two hours, peaking between two and three hours and then declining; rarely a rise is first detected beyond this time. '7 12-14 Oral acetazolamide reaches a peak plasma concentration one hour 'after administration of the drug (Fig. 1) , the greatest fall in IOP occurs after two hours ( Fig. 2 ) and declines only slightly up to six hours."5' Administration of acetazolamide one hour before argon laser trabeculoplasty should produce' maximum IOP reduction to coincide with the period of potential maximum IOP elevation.
Patients and methods
In this controlled study all patients were white, aged 65 After laser treatment the IOP in both eyes and the degree of anterior segment inflammation in the 60 treated eye were determined at 30 minutes, one hour, 8 two hours, three hours, and 24 hours by the classifica- Fig. 4 , and the time at which the maximum lOP increase occurred is shown in Table 1 . One patient with pseudoexfoliative glaucoma in group 2 experienced a rise of 5 mmHg (21%) over the pretreatment IOP at 24 hours; in all other cases the maximum increase had occurred by three hours. Nine patients (18%) in group 1 had a postlaser rise in IOP ranging from I to 8 mmHg, mean 4-3 (SD 3-1) mmHg. The mean rise for the group as a whole was 0-8 (2-1) mmHg. None of the rises in pressure were significant as defined by Krupin et al. 3 In group 2 46 patients (92%) had a postlaser rise in pressure, the range being 1 to 25 mmHg, mean 8-6 (7.1) mmHg. The mean rise for the group as a whole was 7-8 (7-2) mmHg. Fifteen patients (30%) had a significant increase in IOP as defined by Krupin et al.3 In these patients intravenous acetazolamide was administered and produced satisfactory reduction in IOP in all cases.
There was a highly significant increased risk of an immediate postlaser IOP rise in group 2 compared with group 1 (p<0-0001, Fisher's exact test). The amplitude of the rise was also significantly higher in group 2 (p<0-01). We found no significant difference in the risk of a critical postlaser pressure rise between patients with pseudoexfoliation and those without (p>0-3, Fisher's exact test). There was no significant difference in the pressure drop at two months between the two groups; the mean pressure drop for group 1 was 6-8 (4-9) mmHg and for group 2 6-2 (5-5) mmHg. An excessive postlaser rise in intraocular pressure did not significantly compromise the result-Prevention ofthe immediate intraocular pressure risefollow wing argon laser trabeculoplasty ing lOP at two months (Spearman's rank correlation coefficient).
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